2473 related articles for article (PubMed ID: 27748574)
1. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
[TBL] [Abstract][Full Text] [Related]
2. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
[TBL] [Abstract][Full Text] [Related]
3. Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice.
Chen Y; Zhao S; Fan Z; Li Z; Zhu Y; Shen T; Li K; Yan Y; Tian J; Liu Z; Zhang B
Alzheimers Res Ther; 2021 Feb; 13(1):40. PubMed ID: 33563332
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.
Schweig JE; Yao H; Beaulieu-Abdelahad D; Ait-Ghezala G; Mouzon B; Crawford F; Mullan M; Paris D
Acta Neuropathol Commun; 2017 Sep; 5(1):69. PubMed ID: 28877763
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1.
Boutajangout A; Authelet M; Blanchard V; Touchet N; Tremp G; Pradier L; Brion JP
Neurobiol Dis; 2004 Feb; 15(1):47-60. PubMed ID: 14751770
[TBL] [Abstract][Full Text] [Related]
6. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
[TBL] [Abstract][Full Text] [Related]
7. Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice.
Rijal Upadhaya A; Capetillo-Zarate E; Kosterin I; Abramowski D; Kumar S; Yamaguchi H; Walter J; Fändrich M; Staufenbiel M; Thal DR
Neurobiol Aging; 2012 Nov; 33(11):2641-60. PubMed ID: 22305478
[TBL] [Abstract][Full Text] [Related]
8. Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease.
Saul A; Sprenger F; Bayer TA; Wirths O
Neurobiol Aging; 2013 Nov; 34(11):2564-73. PubMed ID: 23747045
[TBL] [Abstract][Full Text] [Related]
9. Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo.
DeVos SL; Corjuc BT; Commins C; Dujardin S; Bannon RN; Corjuc D; Moore BD; Bennett RE; Jorfi M; Gonzales JA; Dooley PM; Roe AD; Pitstick R; Irimia D; Frosch MP; Carlson GA; Hyman BT
Brain; 2018 Jul; 141(7):2194-2212. PubMed ID: 29733334
[TBL] [Abstract][Full Text] [Related]
10. Anti-Aβ antibodies bound to neuritic plaques enhance microglia activity and mitigate tau pathology.
Laversenne V; Nazeeruddin S; Källstig EC; Colin P; Voize C; Schneider BL
Acta Neuropathol Commun; 2020 Nov; 8(1):198. PubMed ID: 33225991
[TBL] [Abstract][Full Text] [Related]
11. Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease.
Howlett DR; Bowler K; Soden PE; Riddell D; Davis JB; Richardson JC; Burbidge SA; Gonzalez MI; Irving EA; Lawman A; Miglio G; Dawson EL; Howlett ER; Hussain I
Histol Histopathol; 2008 Jan; 23(1):67-76. PubMed ID: 17952859
[TBL] [Abstract][Full Text] [Related]
12. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
13. Non-Fibrillar Oligomeric Amyloid-β within Synapses.
Pickett EK; Koffie RM; Wegmann S; Henstridge CM; Herrmann AG; Colom-Cadena M; Lleo A; Kay KR; Vaught M; Soberman R; Walsh DM; Hyman BT; Spires-Jones TL
J Alzheimers Dis; 2016 May; 53(3):787-800. PubMed ID: 27258414
[TBL] [Abstract][Full Text] [Related]
14. Sex Dimorphism Profile of Alzheimer's Disease-Type Pathologies in an APP/PS1 Mouse Model.
Jiao SS; Bu XL; Liu YH; Zhu C; Wang QH; Shen LL; Liu CH; Wang YR; Yao XQ; Wang YJ
Neurotox Res; 2016 Feb; 29(2):256-66. PubMed ID: 26707129
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease.
Pérez M; Morán MA; Ferrer I; Avila J; Gómez-Ramos P
Acta Neuropathol; 2008 Oct; 116(4):409-18. PubMed ID: 18679696
[TBL] [Abstract][Full Text] [Related]
16. (S)-[
Alzghool OM; Rokka J; López-Picón FR; Snellman A; Helin JS; Okamura N; Solin O; Rinne JO; Haaparanta-Solin M
Neuropharmacology; 2021 Sep; 196():108676. PubMed ID: 34216585
[TBL] [Abstract][Full Text] [Related]
17. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.
Kocherhans S; Madhusudan A; Doehner J; Breu KS; Nitsch RM; Fritschy JM; Knuesel I
J Neurosci; 2010 Jul; 30(27):9228-40. PubMed ID: 20610758
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
Chu J; Lauretti E; Craige CP; Praticò D
J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
[TBL] [Abstract][Full Text] [Related]
19. The inside-out amyloid hypothesis and synapse pathology in Alzheimer's disease.
Gouras GK; Willén K; Faideau M
Neurodegener Dis; 2014; 13(2-3):142-6. PubMed ID: 24080821
[TBL] [Abstract][Full Text] [Related]
20. CD40 ligation mediates plaque-associated tau phosphorylation in beta-amyloid overproducing mice.
Laporte V; Ait-Ghezala G; Volmar CH; Ganey C; Ganey N; Wood M; Mullan M
Brain Res; 2008 Sep; 1231():132-42. PubMed ID: 18606155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
